Phaseline

Targets › CD36

CD36 (Platelet glycoprotein 4): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2027.

Multifunctional glycoprotein that acts as a receptor for a broad range of ligands. Ligands can be of proteinaceous nature like thrombospondin, fibronectin, collagen or amyloid-beta as well as of lipidic nature such as oxidized low-density lipoprotein (oxLDL), anionic phospholipids, long- and very long-chain fatty acids and bacterial diacylated lipopeptides. (UniProt, P16671)

Open in Phaseline: the race on CD36, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Pilatus BiosciencesPLT012
anti-CD36 monoclonal antibody
CD36Phase 1Advanced Malignant Solid TumorSep 2027

Conditions

Advanced Malignant Solid Tumor (1)

Modalities

small molecule (1)

Companies

Pilatus Biosciences (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.